Tysabri Progressive Multifocal Leukoencephalopathy Settlement: Statute of Limitations for Tysabri in Texas

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Legal Concerns

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and treatment options. Within this broad domain, the dissemination of knowledge about pharmaceutical interventions and their potential side effects has been a critical function, enabling patients and healthcare providers to make informed decisions. This heritage emphasizes the importance of clear, accessible communication regarding the balance between therapeutic benefits and adverse outcomes, particularly in the context of chronic disease management. As we pivot from this general health framework to a more specific occupational exposure concern, the focus narrows to the legal and temporal dimensions surrounding a particular medication. In the realm of mass production and pharmaceutical liability, the transition involves examining how individuals who have been exposed to a drug—such as through prescribed treatment—may later face complex questions about the timing of legal recourse. This shift requires attention to the statute of limitations, a legal concept that governs the window within which affected parties can seek settlement. In Texas, the application of this statute to cases involving Tysabri exposure and the associated risk of progressive multifocal leukoencephalopathy introduces a distinct layer of concern, moving from general health education to the practical, time-sensitive realities of legal accountability in occupational and clinical settings.

Find Out If You Qualify for Compensation →

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Texas who have developed PML after Tysabri exposure, understanding the medical evidence and legal time limits is critical. The FDA-approved labeling includes a boxed warning stating that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.

Clinical Presentation and Diagnosis of PML

PML is an opportunistic viral infection of the brain caused by the JC virus, typically occurring only in immunocompromised patients, and it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical symptoms may include progressive weakness on one side of the body, visual disturbances, cognitive decline, speech difficulties, and coordination problems. Diagnosis is confirmed through brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. Early recognition is essential because prompt withdrawal of Tysabri may improve outcomes, though many patients still suffer permanent neurological damage.

Mechanistic Pathways Linking Tysabri to PML

The mechanistic link between Tysabri and PML involves reduced immune surveillance in the brain. By blocking lymphocyte migration into the central nervous system, Tysabri prevents the normal immune response that would control JC virus replication. This allows the virus to infect oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The risk is highest in patients with detectable anti-JCV antibodies, indicating prior exposure to the virus. The labeling emphasizes that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Settlement Considerations

The FDA-approved labeling includes a boxed warning that clearly states the risk of PML. However, questions about the adequacy of warnings may arise if patients were not fully informed about the magnitude of risk or the specific risk factors. The labeling requires that Tysabri be prescribed only through the TOUCH Prescribing Program, which mandates regular monitoring and patient education (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients may have developed PML without receiving adequate risk communication, particularly regarding the significance of anti-JCV antibody status and treatment duration. Patients in Texas who have developed PML after Tysabri use may be eligible for compensation through settlements or litigation. Key considerations include the timeline between exposure and documented harm. PML typically occurs after prolonged Tysabri use, often beyond two years, but can develop earlier in patients with additional risk factors. The latency period between starting Tysabri and PML diagnosis can range from months to several years. For settlement purposes, it is important to document the exact dates of Tysabri administration, the date of PML diagnosis, and the presence of any risk factors such as anti-JCV antibodies or prior immunosuppressant use.

Statute of Limitations for Tysabri in Texas

In Texas, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered. For PML cases, the discovery date is typically when the patient receives a confirmed diagnosis. However, Texas law also recognizes a 'discovery rule' that may extend the deadline if the injury was not immediately apparent. Given the severe and often rapidly progressive nature of PML, patients should seek legal counsel promptly after diagnosis to ensure their claim is filed within the applicable time frame. Delays could result in loss of the right to pursue compensation.

Monitoring and Reporting Requirements

The TOUCH Prescribing Program requires that patients be evaluated three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare providers must report cases of PML, hospitalizations due to opportunistic infections, and deaths to Biogen at 1-800-456-2255 as soon as possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These records can be crucial evidence in settlement negotiations.

Conclusion

Tysabri-associated PML is a devastating condition with high morbidity and mortality. For Texas patients, the statute of limitations imposes a strict deadline for filing claims, typically two years from diagnosis. Affected individuals should gather all medical records, including Tysabri administration dates, PML diagnostic tests, and documentation of risk factors, and consult with an attorney experienced in pharmaceutical litigation. The evidence underscores the importance of timely action to preserve legal rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Texas?

In Texas, the statute of limitations for personal injury claims, including those related to Tysabri and PML, is generally two years from the date the injury was discovered or should have been discovered. For PML, this is typically the date of diagnosis. A discovery rule may extend the deadline if the injury was not immediately apparent.

What are the key risk factors for developing PML while on Tysabri?

The three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the FDA-approved labeling (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Tysabri

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.